Kyle A. Beckwith

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan et al. · Blood · 2013 · 796 citations

Life Sciences, Immunology, Pharmacology +14

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

Joseph A. Fraietta, Kyle A. Beckwith, Prachi Patel et al. · Blood · 2016 · 461 citations · Full text

Life Sciences, Immunology, Oncology +12

Ibrutinib treatment improves T cell number and function in CLL patients

Meixiao Long, Kyle A. Beckwith, Priscilla Do et al. · Journal of Clinical Investigation · 2017 · 377 citations · Full text

Life Sciences, Hematology, Immunology +17

Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia

Zachary A. Hing, Rose Mantel, Kyle A. Beckwith et al. · Blood · 2015 · 95 citations · Full text

Medicine, Oncology, Pharmacology +7

Toll-Like Receptors and Dectin-1, a C-Type Lectin Receptor, Trigger Divergent Functions in CNS Macrophages

John C. Gensel, Yan Wang, Zhen Guan et al. · Journal of Neuroscience · 2015 · 77 citations · Full text

Life Sciences, Immunology, Neuroscience +17